Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07631325 · ClinicalTrials.gov registry record · Phase 1
Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma
A Phase 1 study, sponsored by John Kirkwood.
- Not yet
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT07631325 is a Phase 1 study that has not yet begun recruiting, run by John Kirkwood. The registered enrollment target is 28 participants.
The verdict
NCT07631325, a Phase 1 study, has not yet begun recruiting, sponsored by John Kirkwood.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.
Interventions
- DRUG Nivolumab
- DRUG Axelopran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07631325
The ClinicalTrials.gov registry entry for NCT07631325 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07631325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07631325 about?
NCT07631325 is a clinical study titled "Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma". This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotypin...
What is the current status of trial NCT07631325?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-07-31. Estimated completion is 2030-07-31.
What interventions are being tested in trial NCT07631325?
The interventions under investigation include: Nivolumab (DRUG), Axelopran (DRUG).
Who is sponsoring clinical trial NCT07631325?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.